Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Innov Card Rhythm Manag ; 10(2): 3541-3544, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32477718

RESUMO

A 24-year-old female presented to our clinic with symptomatic tachycardia. In the clinic, she was able to replicate her symptoms, which were due to tachycardia in a standing position that resolved upon sitting. The patient was then offered eight ounces (236.6 mL) of water and, after consumption of such, the standing tachycardia was no longer observed. A diagnosis of postural orthostatic tachycardia syndrome (POTS) was made. This case report discusses a novel approach to acute treatment for POTS.

2.
BMJ Case Rep ; 20182018 Feb 27.
Artigo em Inglês | MEDLINE | ID: mdl-29487102

RESUMO

We present the case of a patient who presented with worsening chest pain and tachycardia. We were able to monitor her remotely through her pacemaker. She had been started on the injectable medication teriparatide (Forteo) and since then she had an increase in her symptoms. She was found to have intermittent atrial tachycardia with 1:1 conduction and occasional atrioventricular block transiently, coinciding with her injection of teriparatide. This specific-associated arrhythmia has yet to be described.


Assuntos
Conservadores da Densidade Óssea/efeitos adversos , Eletrocardiografia/efeitos dos fármacos , Taquicardia/induzido quimicamente , Teriparatida/efeitos adversos , Idoso , Diagnóstico Diferencial , Feminino , Humanos , Taquicardia/diagnóstico
3.
BMJ Case Rep ; 20182018 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-29301810

RESUMO

We present the case of a patient who presented with acute coronary syndrome and was found to have a mass compressing the left atrium. An angiogram revealed a large saphenous vein graft aneurysm with a fistula into a cardiac chamber, presumed to be the left ventricle. The patient also developed a functional mitral stenosis secondary to this mass causing left atrial compression. The patient passed away prior to receiving surgery. We describe a rare case of venous graft aneurysm with compression and fistula to a chamber other than the right atrium, that to our knowledge has yet to be reported.


Assuntos
Aneurisma/diagnóstico por imagem , Fístula Arteriovenosa/diagnóstico , Estenose da Valva Mitral/diagnóstico , Veia Safena/transplante , Idoso , Aneurisma/complicações , Fístula Arteriovenosa/etiologia , Fístula Arteriovenosa/patologia , Diagnóstico Diferencial , Evolução Fatal , Átrios do Coração/patologia , Humanos , Masculino , Veia Safena/diagnóstico por imagem
4.
J Innov Card Rhythm Manag ; 9(10): 3365-3368, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32477786

RESUMO

Complications of atrial fibrillation ablation include pericardial effusion, which tends to occur acutely. Large and hemodynamically important effusions are uncommon, but a small effusion may be present at the end of the procedure in up to 22% of ablations. We monitor for pericardial effusions routinely after ablation with intracardiac echocardiography. However, the follow-up of a small effusion present immediately after ablation remains uncertain, especially with the use of dabigatran or another novel oral anticoagulant. There are no current recommendations on the follow-up of small pericardial effusions after ablation. We present a case and ask a panel of experts for their opinions.

5.
Ochsner J ; 16(3): 312-4, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27660583

RESUMO

BACKGROUND: Acute renal infarction (ARI) is an uncommon and often overlooked diagnosis in patients presenting with acute kidney injury and abdominal pain. CASE REPORTS: We present 2 cases of ARI in the setting of atrial fibrillation along with a review of medical literature pertaining to ARI. CONCLUSION: This article should aid clinicians in the diagnosis of ARI.

6.
J Clin Med Res ; 8(2): 111-5, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26767079

RESUMO

BACKGROUND: Chest pain (CP) is a frequent cause of emergency room visits in United States and adds a huge financial burden to our healthcare cost. With the addition of observation units, standard CP protocols have shown to decrease length of stay (LOS) and cost per discharge (CPD). We report our experience with the development and implementation of "CP protocol for intermediate cardiac risk patients" and its impact on healthcare resource utilization at our medical center. METHODS AND RESULTS: We retrospectively analyzed 30 patients who presented to Advocate Christ Medical Center (ACMC) with CP and were considered to be at intermediate risk for acute coronary syndrome after obtaining IRB approval. Patients were treated with our standardized CP protocol and labeled as "protocol patients". Our control group consisted of patients with similar demographics and diagnosis but not treated with our CP protocol admitted in the same time period and under our own faculty. This helped remove the bias of different treating attending. Our protocol algorithm consisted of medications, an electrocardiogram (EKG), cardiac troponin I level, and a stress test if indicated. Primary clinical endpoints for this study were LOS in hours and CPD for patients in our protocol group compared to control group. LOS in the protocol group was lower compared to the control but the difference was not statistically significant (P = 0.74). The average CPD in the control group (mean = $13,446) was almost $830 more than the protocol group (mean = $14,276, P = 0.827). CONCLUSION: Implementation of standardized protocols for patients with CP has proven to be a cost effective strategy at several institutions across the country. Our study showed a reduction in CPD although not statistically significant. LOS was also reduced but did not meet statistical significance mainly due to our small sample size. Previous studies had demonstrated much larger savings between a protocol-driven group and a non-protocol-driven group. On further analysis of our data, our protocol group contained five patients who underwent invasive diagnostic tests including computed tomography for pulmonary embolism scans which were not present in the control group. This accounted for the small reduction in costs for the protocol group.

7.
J Clin Med Res ; 7(9): 720-3, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26251689

RESUMO

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease primarily involving the joint synovium. RA is a systemic disease which has many known extra-articular manifestations. We present a unique case of a patient with long standing RA who presented with a primary complaint of chest and back pain. Echocardiography revealed borderline normal left ventricular function and a large pericardial effusion with the finding of elevated intrapericardial pressure suspicious for cardiac tamponade. Infectious workup was all found to be negative. The presence and elevation of anti-cyclic citrullinated peptide antibody, rheumatoid factor and C-reactive protein (CRP) confirmed the patient was having an active flare-up of RA. It was determined that this flare-up was the cause of the cardiac tamponade. A pericardiocentesis was performed and 850 mL of bloody fluid was drained. The patient remained stable following the pericardiocentesis. At his follow-up visit, repeat echocardiogram showed no signs for pericardial effusion. Although there has been extensive study of RA, there are only a few documented cases noting the occurrence of cardiac tamponade in these patients. Therefore, it is important for the clinician to be aware of and recognize this potentially serious cardiac outcome associated with a common rheumatologic condition.

8.
J Cardiol Cases ; 12(4): 126-129, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30546575

RESUMO

There have been few cases in recent times where QT interval prolongation has been studied with regards to the use of diphenhydramine. We present a case of a patient who presented because of shortness of breath and needed emergent hemodialysis; during the course of which he developed prolonged QT interval on electrocardiography, which was correlated interestingly with the use of diphenhydramine. Pruritus is a common symptom experienced by dialysis patients. A less known, but rare side effect of diphenhydramine is prolongation of QT interval. The histamine H1 receptor antagonist diphenhydramine inhibits the fast sodium channels and at higher concentrations inhibits the repolarizing potassium channels which leads to prolongation of the action potential and the QT interval. Diphenhydramine toxicity is dose-dependent with a critical dose limit of 1.0 g. Although a lot is known about the potential side effects of antihistamines, only a few cases have cited the cardiac side effects. Thus, it is important for the clinician to be aware of this potentially serious consequence of a commonly used drug, especially in the end-stage renal disease population. It is important for clinicians to be aware of this rare yet dangerous side effect of diphenhydramine. .

9.
Ochsner J ; 15(4): 418-22, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26730226

RESUMO

BACKGROUND: Respiratory depression is a common adverse effect of benzodiazepine administration to patients with severe alcoholic withdrawal. This study was conducted to assess the value of end tidal carbon dioxide (ETCO2) levels compared to partial pressure of arterial carbon dioxide (PaCO2) levels in monitoring respiratory depression secondary to benzodiazepine treatment in patients with severe alcohol withdrawal. METHODS: We retrospectively analyzed 36 patients admitted to the intensive care unit for severe alcohol withdrawal who had been administered sedative agents. RESULTS: We observed a statistically significant correlation between PaCO2 and ETCO2 at time 1 (r=0.74, P<0.01) and time 3 (r=0.52, P=0.02) but not at time 2 (r=0.22, P=0.31). CONCLUSION: Our study confirms a positive correlation between PaCO2 and ETCO2 levels in patients experiencing severe alcohol withdrawal.

10.
Cancer Res ; 65(14): 6282-93, 2005 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-16024630

RESUMO

Patients with metastatic melanoma or multiple myeloma have a dismal prognosis because these aggressive malignancies resist conventional treatment. A promising new oncologic approach uses molecularly targeted therapeutics that overcomes apoptotic resistance and, at the same time, achieves tumor selectivity. The unexpected selectivity of proteasome inhibition for inducing apoptosis in cancer cells, but not in normal cells, prompted us to define the mechanism of action for this class of drugs, including Food and Drug Administration-approved bortezomib. In this report, five melanoma cell lines and a myeloma cell line are treated with three different proteasome inhibitors (MG-132, lactacystin, and bortezomib), and the mechanism underlying the apoptotic pathway is defined. Following exposure to proteasome inhibitors, effective killing of human melanoma and myeloma cells, but not of normal proliferating melanocytes, was shown to involve p53-independent induction of the BH3-only protein NOXA. Induction of NOXA at the protein level was preceded by enhanced transcription of NOXA mRNA. Engagement of mitochondrial-based apoptotic pathway involved release of cytochrome c, second mitochondria-derived activator of caspases, and apoptosis-inducing factor, accompanied by a proteolytic cascade with processing of caspases 9, 3, and 8 and poly(ADP)-ribose polymerase. Blocking NOXA induction using an antisense (but not control) oligonucleotide reduced the apoptotic response by 30% to 50%, indicating a NOXA-dependent component in the overall killing of melanoma cells. These results provide a novel mechanism for overcoming the apoptotic resistance of tumor cells, and validate agents triggering NOXA induction as potential selective cancer therapeutics for life-threatening malignancies such as melanoma and multiple myeloma.


Assuntos
Ácidos Borônicos/farmacologia , Melanoma/tratamento farmacológico , Mieloma Múltiplo/tratamento farmacológico , Inibidores de Proteases/farmacologia , Inibidores de Proteassoma , Proteínas Proto-Oncogênicas c-bcl-2/fisiologia , Pirazinas/farmacologia , Animais , Apoptose/efeitos dos fármacos , Bortezomib , Feminino , Humanos , Melanócitos/citologia , Melanócitos/efeitos dos fármacos , Melanoma/enzimologia , Melanoma/patologia , Camundongos , Camundongos Nus , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/fisiologia , Mieloma Múltiplo/enzimologia , Mieloma Múltiplo/patologia , Oligonucleotídeos Antissenso/genética , Proteínas Proto-Oncogênicas c-bcl-2/antagonistas & inibidores , Proteínas Proto-Oncogênicas c-bcl-2/biossíntese , Proteínas Proto-Oncogênicas c-bcl-2/genética , RNA Mensageiro/biossíntese , RNA Mensageiro/genética , Proteína Supressora de Tumor p53/fisiologia , Ensaios Antitumorais Modelo de Xenoenxerto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...